BioNexus Gene Lab Corp. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
BioNexus Gene Lab Corp. (BGLC) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $666.48 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-08-14
- BioNexus Gene Lab Corp. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2026-06-30 was $112.03K, a 80.19% decline year-over-year.
- BioNexus Gene Lab Corp. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2026-03-31 was $554.45K, a 10.99% decline year-over-year.
- BioNexus Gene Lab Corp. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2025-06-30 was $565.49K.
- BioNexus Gene Lab Corp. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2025-03-31 was $622.93K.
- BioNexus Gene Lab Corp. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $2.20M, a 3.16% increase from fiscal 2024.
- BioNexus Gene Lab Corp. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $2.14M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 3 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 6 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|---|---|
| 2026-06-30 | $112.03K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $666.48K 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $554.45K 10-Q · filed 2026-05-15 | ||
| 2025-12-31 | $2.20M 10-K · filed 2026-04-14 | ||
| 2025-06-30 | $565.49K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $1.19M 10-Q · filed 2026-08-14 | |
| 2025-03-31 | $622.93K 10-Q · filed 2026-05-15 | ||
| 2024-12-31 | $2.14M 10-K · filed 2026-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |